Search
Arbaclofen Placarbil
go.drugbank.com/drugs/DB08892InvestigationalArbaclofen Placerbil is a prodrug of Arbaclofen, which is a selective gamma-amino-butyric acid type B receptor agonist and the R-enantiomer of baclofen. … It was discovered, and has been patented by XenoPort as a new chemical entity with an improved pharmacokinetic profile compared to baclofen, which allows for sustained release properties.
Categories: GABA-B Receptor AgonistsAclidinium
go.drugbank.com/drugs/DB08897ApprovedAclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). … It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.
Mixtures: DUAKLIR®GENUAIR®340/12MCG/DOSIS.Products: EKLIRA®GENUAIR® 322 MCG/DOSISEnzalutamide
go.drugbank.com/drugs/DB08899ApprovedInvestigational[A252667,A252642] Due to a favorable pharmacological profile, a phase 1 study of enzalutamide was initiated in July 2007. … [L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012.
Categories: P-glycoprotein inhibitors, Cytochrome P-450 SubstratesProducts: XTANDI ® 40 MG, XTANDI® 40 MGRaxibacumab
go.drugbank.com/drugs/DB08902ApprovedInvestigationalRaxibacumab is a human IgG1λ monoclonal antibody that binds the protective antigen (PA) component of B. anthracis toxin. Raxibacumab has a molecular weight of approximately 146 kilodaltons. … Raxibacumab is produced by recombinant DNA technology in a murine cell expression system. FDA approved on December 14, 2012.
Formestane
go.drugbank.com/drugs/DB08905ApprovedWithdrawnIt is listed as a prohibited substance by the World Anti-Doping Agency for use in athletes. … Formestane is also a prohormone of 4-hydroxytestosterone, an active steroid with weak androgenic activity and mild aromatase inhibitor activity.
Synonyms: 4-OH-A, 4-hydroxy-4-androstene-3,17-dioneCategories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A4 InducersFluticasone furoate
go.drugbank.com/drugs/DB08906ApprovedInvestigationalFluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].
Mixtures: RELVAR® ELLIPTA® 100MCG/25MCG, RELVAR® ELLIPTA ® 200MCG/25MCG POLVO PARA INHALACIÓNCategories: P-glycoprotein inducers, P-glycoprotein substratesAleglitazar
go.drugbank.com/drugs/DB08915InvestigationalAleglitazar is an investigational drug from the company Hoffmann–La Roche and is currently in a phase III clinical trial called ALECARDIO. … It is being investigated for use in patients with type II diabetes to reduce their risks of cardiovascular mortality and morbidity.
Categories: Heterocyclic Compounds, 1-Ring(4R)-limonene
go.drugbank.com/drugs/DB08921InvestigationalAs the main odor constituent of citrus (plant family Rutaceae), D-limonene is used in food manufacturing and some medicines, e.g. as a flavoring to mask the bitter taste of alkaloids, and as a fragrant … Limonene is common in cosmetic products.
Synonyms: (R)-4-isopropenyl-1-methyl-1-cyclohexene, (R)-1-methyl-4-(1-methylethenyl)cyclohexeneAcediasulfone
go.drugbank.com/drugs/DB08926ExperimentalAcediasulfone (INN) is an antimicrobial and antimalarial long-acting prodrug of dapsone.
Dolutegravir
go.drugbank.com/drugs/DB08930ApprovedInvestigationalDolutegravir is an HIV-1 integrase inhibitor that blocks the strand transfer step of the integration of the viral genome into the host cell (INSTI). … [L1035] On November 21, 2017, dolutegravir, in combination with rilpivirine, was approved as part of the first complete treatment regimen with only two drugs for the treatment of adults with HIV-1 named
Mixtures: TRIUMEQ® 50 MG / 600 MG / 300 MGCategories: MATE 1 Inhibitors, P-glycoprotein substrates